Association of Liver Histology with Sonological Grading and Liver Stiffness Measured by Fibroscan in Patients with NAFLD

Background: Non-alcoholic fatty liver disease (NAFLD) is theterm for a range of situations caused by a build-up of fat inthe liver. It's usually seen in people who are obese.Objective: In this study our main goal is to evaluate theassociation of liver histology with sonological grading and liverstiffness measured by Fibroscan in patients with NAFLD.Methods: This cross-sectional study was done at Departmentof Hepatology, Bangabandhu Sheikh Mujib Medical Universityfrom July 2007 to June 2009. Total 45 patients of fatty liverdisease were studied. All collected data was recorded in astructured questionnaire and was analyzed by SPSS version20. Values were expressed either as mean + SD or infrequency or in percentages.Results: During the study majority of the patients were 30-50years old (73.33 %), which indicates that the patients weresomewhat younger and out of 45 of study population 21(46.7%) patients was grade I fatty liver, 23(51.1%) were gradeII fatty liver and only one (2.2%) was grade III fatty liver. Thisstudy also showed that correlation between fibroscan of liverand grading of fibrosis in liver histology reveals significantassociation.

Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan

BACKGROUND/AIMS: It is important to determine the noninvasive parameters of histological features in nonalcoholic fatty liver disease (NAFLD). The aim of this study was to investigate the value of genetic variations as surrogate markers of histological features. METHODS: The parameters that affected the histological features of NAFLD were investigated in 211 Japanese patients with biopsy-proven NAFLD. The relationships between genetic variations in PNPLA3 rs738409 or TM6SF2 rs58542926 and histological features were analyzed. Furthermore, the impact of genetic variations that affected the pathological criteria for the diagnosis of nonalcoholic steatohepatitis (NASH) (Matteoni classification and NAFLD activity score) was evaluated. RESULTS: The fibrosis stage of PNPLA3 GG was significantly more progressive than that of CG by multiple comparisons. Multivariate analysis identified PNPLA3 genotypes as predictors of fibrosis of stage 2 or more, but the impact tended to decrease at stage 3 or greater. There were no significant differences among the histological features of the three genotypes of TM6SF2. PNPLA3 genotypes partly affected the definition of NASH by the NAFLD activity score, but TM6SF2 genotypes did not affect the definition of NASH. CONCLUSIONS: In Japanese patients with biopsy-proven NAFLD, PNPLA3 genotypes may partly affect histological features, including stage of fibrosis, but the TM6SF2 genotype does not affect histological features.

Predictors of histological activity and fibrosis in chronic Hepatitis C infection: A study from North India.

Background and Aims: The role of hepatitis C virus (HCV) genotypes in the severity of liver disease is still debatable and there is an occasional published report from India. The aim of this study is to assess the role of HCV genotypes in severity of liver disease in Indian patients. An attempt has also been made to perform a multivariate analysis to identify the predictors of severity of liver disease in chronic HCV infection. Materials and Methods: In this study, 31 newly diagnosed cases of chronic HCV infection over a period of two years were included. Age, sex and serum alanine transaminase (ALT) levels were recorded for each patient. HCV genotypes were identified using Line Probe assay (INNO-LiPA HCV II kit, Innogenetics, Belgium). Histological activity was graded and fibrosis was staged. Univariate and multivariate analysis was done to identify predictors of histological severity and fibrosis. Results: By univariate analysis, age of the patient, serum ALT levels and absence of genotype 3 (i.e., presence of HCV genotype other than genotype 3) showed association with histological activity score; whereas age and histological activity score showed association with fibrosis. However, on multivariate analysis, only serum ALT levels and absence of genotype 3 correlated well with activity score; while only activity score remained a significant predictor of stage of fibrosis. Conclusions: This study emphasizes the significant correlation of HCV genotype with severity of liver disease in chronic HCV infection. The stage of fibrosis showed correlation only with activity score as an independent factor. These results would further help in outlining algorithms for therapeutic stratification of patients with HCV infection.

Factors associated with liver stiffness in chronic liver disease / 대한간학회지

BACKGROUND/AIMS: Transient elastography is a new noninvasive tool for measuring liver stiffness that accurately predicts significant fibrosis and cirrhosis. However, several studies have indicated that liver stiffness can be significantly influenced by major changes in aminotransferase in patients with chronic viral hepatitis. The aim of this study was to determine the factors influencing liver stiffness in patients with chronic liver disease. METHODS: We studied 158 patients with chronic liver disease who underwent transient elastography and liver biopsy sampling. Histologic findings on fibrosis and necroinflammatory activity in the biopsy specimens were evaluated according to the Korean Society of Pathologists Scoring System. Routine biochemical tests were performed according to standard methods. RESULTS: Liver stiffness was strongly correlated with liver fibrosis stage (Spearman coefficient=0.636, P<0.001), lobular activity (Spearman coefficient=0.359, P<0.001), and portoperiportal activity grade (Spearman coefficient=0.448, P<0.001). Liver stiffness was significantly associated with serum levels of total bilirubin (P=0.025), direct bilirubin (P=0.049), gamma-glutamyl transpeptidase (P=0.014), platelet count (P=0.004), albumin (P<0.001), and international normalized ratio (P<0.001). Multivariate analysis showed that fibrosis stage (B 3.50, P=0.009) and lobular activity grade (B 3.25, P=0.047) were independently associated with liver stiffness. CONCLUSIONS: Liver stiffness as measured by transient elastography is associated with the grade of necroinflammatory activity and the stage of fibrosis, irrespective of serum ALT levels.

Histología de la biopsia hepática, enfoque para el clínico / Histopathology of the liver biopsy, clinical approach

La biopsia hepática es necesaria para la evaluación de la hepatitis crónica. Su utilidad reside en la valoración del grado de inflamación y fibrosis del paciente con hepatitis crónica. La utilización de un sistema semicuantitativo para la clasificación de las biopsias de hepatitis crónicas es necesaria con el fin de tener parámetros menos subjetivos, y para comparar la evolución ante una potencial terapia. Se establece una puntuación semicuantitativa que determina la graduación y el estadiaje. Se considera importante tener como mínimo para la valoración de una biopsia hepática, la presencia al menos de 3-5 espacios porta y realizar tinciones de rutina como hematoxilina eosina, tricromico, reticulita y orceina. Se considera básico para la definición de los tratamientos la actividad inflamatoria y el estadio de la fibrosis, apoyando a la parte clínica, bioquímica y de biología molecular del virus de hepatitis B.

The hepatic biopsy is necessary for the evaluation of chronic hepatitis. Its usefulness is relies on the assessment of the inflammation degree and fibrosis of the patient with chronic hepatitis. The use of a semi quantitative system for the classification of chronic hepatitis biopsies is necessary to keep less subjective parameters and to compare its evolution for a potential therapy. A semi quantitative score is established to determine the degree and staging. For the assessment of a hepatic biopsy, it is important to get at least 3-5 porta spaces and perform routine tinctions as hematoxylin-eosin, trichromic, reticulite and orcein. This is essential for the definition of treatments, inflammatory activity and fibrosis stage, supporting the clinical, biochemical, and molecular biology parts of the viral burden of the hepatitis B virus.